Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DraftKings Inc (DKNG) vs Summit Therapeutics Inc (SMMT) Price & Performance

DraftKings IncTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

DraftKings Inc vs Summit Therapeutics Inc — how do they compare? DraftKings Inc trades at $25.41 (market cap $12.58B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: DraftKings Inc and Summit Therapeutics Inc are close in size by market cap. Which is the better fit depends on your goals.

DKNGSMMT
Market Cap
$12.58B$12.06B
Sector
Consumer CyclicalHealth
52-Week High
$48.23$26.98
52-Week Low
$20.72$12.55
Enterprise Value
$13.51B$11.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DraftKings Inc

DraftKings (DKNG) trades at $25.79, up 6.24% on the day, with a bullish technical signal and strong analyst consensus. Revenue grew to $6.05 billion in 2025, though recent quarters show earnings misses. The company is expanding into prediction markets, with CEO Jason Robins highlighting rapid growth ahead of the NFL season (Bloomberg Technology, 2026-08-07).

The outlook is mixed: strong revenue growth and positive cash flow from operations contrast with high valuation multiples and recent profitability challenges. Key risks include competition from prediction markets and promotional costs pressuring margins. The consensus price target of $34.00 suggests upside potential if execution improves.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About DraftKings Inc

DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.

Read more on DKNG

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT